• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于根除后在低防护条件下生产灭活脊髓灰质炎疫苗的新毒株

New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication.

作者信息

Knowlson Sarah, Burlison John, Giles Elaine, Fox Helen, Macadam Andrew J, Minor Philip D

机构信息

Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.

出版信息

PLoS Pathog. 2015 Dec 31;11(12):e1005316. doi: 10.1371/journal.ppat.1005316. eCollection 2015 Dec.

DOI:10.1371/journal.ppat.1005316
PMID:26720150
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4699825/
Abstract

Poliomyelitis has nearly been eradicated through the efforts of the World Health Organization's Global Eradication Initiative raising questions on containment of the virus after it has been eliminated in the wild. Most manufacture of inactivated polio vaccines currently requires the growth of large amounts of highly virulent poliovirus, and release from a production facility after eradication could be disastrous; WHO have therefore recommended the use of the attenuated Sabin strains for production as a safer option although it is recognised that they can revert to a transmissible paralytic form. We have exploited the understanding of the molecular virology of the Sabin vaccine strains to design viruses that are extremely genetically stable and hyperattenuated. The viruses are based on the type 3 Sabin vaccine strain and have been genetically modified in domain V of the 5' non-coding region by changing base pairs to produce a cassette into which capsid regions of other serotypes have been introduced. The viruses give satisfactory yields of antigenically and immunogenically correct viruses in culture, are without measurable neurovirulence and fail to infect non-human primates under conditions where the Sabin strains will do so.

摘要

通过世界卫生组织全球根除脊髓灰质炎行动的努力,脊髓灰质炎几乎已被根除,这引发了在该病毒在自然界中被消灭后如何控制它的问题。目前,大多数灭活脊髓灰质炎疫苗的生产需要培养大量高致病性脊髓灰质炎病毒,而在根除后从生产设施中释放这些病毒可能会带来灾难性后果;因此,世卫组织建议使用减毒的萨宾毒株进行生产,认为这是一个更安全的选择,尽管人们认识到它们可能会回复到可传播的麻痹形式。我们利用对萨宾疫苗株分子病毒学的认识,设计出了遗传上极其稳定且高度减毒的病毒。这些病毒基于3型萨宾疫苗株,通过改变碱基对在5'非编码区的V结构域进行了基因改造,以产生一个盒式结构,其他血清型的衣壳区域已被引入该盒式结构中。这些病毒在培养中能产生抗原性和免疫原性正确的病毒,产量令人满意,没有可测量的神经毒性,并且在萨宾毒株能够感染非人类灵长类动物的条件下,它们无法感染非人类灵长类动物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/7b36fade2036/ppat.1005316.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/d6335a790646/ppat.1005316.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/eae1e857ca14/ppat.1005316.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/ed0983f560b0/ppat.1005316.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/7b36fade2036/ppat.1005316.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/d6335a790646/ppat.1005316.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/eae1e857ca14/ppat.1005316.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/ed0983f560b0/ppat.1005316.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7167/4699825/7b36fade2036/ppat.1005316.g004.jpg

相似文献

1
New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication.用于根除后在低防护条件下生产灭活脊髓灰质炎疫苗的新毒株
PLoS Pathog. 2015 Dec 31;11(12):e1005316. doi: 10.1371/journal.ppat.1005316. eCollection 2015 Dec.
2
Development of inactivated poliovirus vaccine from Sabin strains: A progress report.基于萨宾株的灭活脊髓灰质炎病毒疫苗的研发:进展报告。
Biologicals. 2016 Nov;44(6):581-587. doi: 10.1016/j.biologicals.2016.08.005. Epub 2016 Oct 5.
3
An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.脊髓灰质炎病毒简介:发病机制、疫苗接种及全球根除的最终目标
Methods Mol Biol. 2016;1387:1-10. doi: 10.1007/978-1-4939-3292-4_1.
4
Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.疫苗衍生脊髓灰质炎病毒(VDPV):对根除脊髓灰质炎的影响。
Vaccine. 2009 May 5;27(20):2649-52. doi: 10.1016/j.vaccine.2009.02.071. Epub 2009 Mar 3.
5
Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.三种血清型基因稳定的减毒活脊髓灰质炎病毒疫苗的合理设计:与根除脊髓灰质炎的相关性
J Virol. 2006 Sep;80(17):8653-63. doi: 10.1128/JVI.00370-06.
6
Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.与使用减毒活疫苗脊灰病毒株相关的风险,以及控制和消灭麻痹性脊髓灰质炎的策略。
Expert Rev Vaccines. 2012 May;11(5):609-28. doi: 10.1586/erv.12.28.
7
Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.免疫缺陷个体中脊髓灰质炎病毒复制28年:对全球根除脊髓灰质炎行动的影响
PLoS Pathog. 2015 Aug 27;11(8):e1005114. doi: 10.1371/journal.ppat.1005114. eCollection 2015 Aug.
8
Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines.基因热稳定、具有免疫原性的脊髓灰质炎病毒空衣壳;一种非复制性疫苗的策略。
PLoS Pathog. 2017 Jan 19;13(1):e1006117. doi: 10.1371/journal.ppat.1006117. eCollection 2017 Jan.
9
Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.消灭脊灰:全世界的儿科医生如何助力永远终结这种致残疾病
Pediatrics. 2015 Jan;135(1):196-202. doi: 10.1542/peds.2014-3163.
10
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.两种新型口服减毒单价(血清型 2)脊灰病毒疫苗在健康成年人中的安全性和免疫原性:一项双盲、单中心 1 期研究。
Lancet. 2019 Jul 13;394(10193):148-158. doi: 10.1016/S0140-6736(19)31279-6. Epub 2019 Jun 4.

引用本文的文献

1
Genetic characterization of type 3 vaccine-derived poliovirus from a patient with hand, foot, and mouth disease in China.中国一名手足口病患者中3型疫苗衍生脊髓灰质炎病毒的基因特征分析
Virol J. 2025 Jun 28;22(1):208. doi: 10.1186/s12985-025-02827-2.
2
Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation.利用受控发酵在酵母中生产具有免疫原性的三价脊髓灰质炎病毒样颗粒候选疫苗。
NPJ Vaccines. 2025 Mar 31;10(1):64. doi: 10.1038/s41541-025-01111-2.
3
Complete genome sequences of six S19 poliovirus reference strains.

本文引用的文献

1
Live attenuated vaccines: Historical successes and current challenges.减毒活疫苗:历史上的成功与当前的挑战。
Virology. 2015 May;479-480:379-92. doi: 10.1016/j.virol.2015.03.032. Epub 2015 Apr 8.
2
Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.在日本开发和引进源自 Sabin 株的脊髓灰质炎灭活疫苗。
Vaccine. 2016 Apr 7;34(16):1975-85. doi: 10.1016/j.vaccine.2014.11.015. Epub 2014 Nov 21.
3
The polio-eradication programme and issues of the end game.脊髓灰质炎根除计划和终局问题。
六种S19脊髓灰质炎病毒参考毒株的全基因组序列
Microbiol Resour Announc. 2024 Jul 18;13(7):e0008024. doi: 10.1128/mra.00080-24. Epub 2024 Jun 18.
4
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance.灭活脊髓灰质炎疫苗:最新进展及走向全球认可的曲折历程
Pathogens. 2024 Mar 4;13(3):224. doi: 10.3390/pathogens13030224.
5
Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3.遗传稳定减毒口服疫苗对脊髓灰质炎病毒 1 型和 3 型的作用。
Nature. 2023 Jul;619(7968):135-142. doi: 10.1038/s41586-023-06212-3. Epub 2023 Jun 14.
6
High-throughput analysis of anti-poliovirus neutralization antibody titre in human serum by the pseudovirus neutralization test.应用假病毒中和试验对人血清中抗脊髓灰质炎病毒中和抗体效价进行高通量分析。
Sci Rep. 2022 Sep 27;12(1):16074. doi: 10.1038/s41598-022-20544-6.
7
Evolving pharmacovigilance requirements with novel vaccines and vaccine components.新型疫苗和疫苗成分带来的药物警戒要求变化。
BMJ Glob Health. 2021 May;6(Suppl 2). doi: 10.1136/bmjgh-2020-003403.
8
Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.新型 Sabin 灭活脊灰病毒候选疫苗在 PER.C6®细胞系上生产的安全性和免疫原性:一项在成人中进行的 1 期随机对照试验。
Hum Vaccin Immunother. 2021 May 4;17(5):1366-1373. doi: 10.1080/21645515.2020.1812315. Epub 2020 Nov 11.
9
Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.更新 2019-2029 年暴发应对策略的特征描述:使用新型 2 型口服脊髓灰质炎疫苗株的影响。
Risk Anal. 2021 Feb;41(2):329-348. doi: 10.1111/risa.13622. Epub 2020 Nov 10.
10
The role of genetic sequencing and analysis in the polio eradication programme.基因测序与分析在脊髓灰质炎根除计划中的作用。
Virus Evol. 2020 May 20;6(2):veaa040. doi: 10.1093/ve/veaa040. eCollection 2020 Jul.
J Gen Virol. 2012 Mar;93(Pt 3):457-474. doi: 10.1099/vir.0.036988-0. Epub 2011 Nov 29.
4
Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.三种血清型基因稳定的减毒活脊髓灰质炎病毒疫苗的合理设计:与根除脊髓灰质炎的相关性
J Virol. 2006 Sep;80(17):8653-63. doi: 10.1128/JVI.00370-06.
5
A global call for new polio vaccines.全球呼吁研发新型脊髓灰质炎疫苗。
Nature. 2005 Apr 7;434(7034):699-700. doi: 10.1038/434699a.
6
Pathogenesis of poliomyelitis; reappraisal in the light of new data.脊髓灰质炎的发病机制;根据新数据重新评估。
Science. 1956 Jun 29;123(3209):1151-7. doi: 10.1126/science.123.3209.1151.
7
Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains.由减毒活疫苗株制备的甲醛灭活脊髓灰质炎病毒制剂的特性研究
J Gen Virol. 2003 Jul;84(Pt 7):1781-1788. doi: 10.1099/vir.0.19088-0.
8
Coding changes in the poliovirus protease 2A compensate for 5'NCR domain V disruptions in a cell-specific manner.脊髓灰质炎病毒蛋白酶2A中的编码变化以细胞特异性方式补偿5'非编码区结构域V的破坏。
Virology. 2000 Apr 10;269(2):284-93. doi: 10.1006/viro.2000.0244.
9
Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro.表达人脊髓灰质炎病毒受体的L细胞的特性,用于体外脊髓灰质炎病毒的特异性检测。
J Virol Methods. 1993 Mar;41(3):333-40. doi: 10.1016/0166-0934(93)90022-j.
10
Potency testing of killed polio vaccine in rats.大鼠中灭活脊髓灰质炎疫苗的效力测试。
Dev Biol Stand. 1981;47:119-28.